Johnson & Johnson maintained its position as the top pharmaceutical company by revenue in 2025, while Eli Lilly experienced significant growth driven by strong sales of its obesity and diabetes drug tirzepatide, according to a March 18 report.
The ranking highlights ongoing shifts in the pharmaceutical industry, with companies adapting to changing market conditions and focusing on new therapeutic areas. The performance of these leading firms reflects broader trends such as patent expirations, increased competition in weight-loss treatments, and strategic investments in research and development.
Johnson & Johnson reported $94.19 billion in revenue for 2025, a 6% increase from the previous year. Despite losing exclusivity for its immunology drug Stelara—which saw sales drop by 41%—the company offset losses through newer products like Tremfya and Simponi, which grew nearly 40% and 22%, respectively. J&J's oncology division also contributed significantly, with cancer drugs accounting for more than a quarter of total revenue.
Roche held onto second place with $79.48 billion in revenue, up 7%. Its top-selling product was Ocrevus for multiple sclerosis, followed by Hemlibra for hemophilia A and Xolair for asthma. Roche also engaged in major acquisitions during the year to strengthen its pipeline.
Eli Lilly jumped to third place after a record-breaking year that saw revenues rise by 45% to $65.18 billion. The company's success was largely attributed to tirzepatide (marketed as Mounjaro for diabetes and Zepbound for weight loss), which posted strong sales growth. Studies have shown tirzepatide offers better weight-loss and glucose control compared to competitors' drugs.
Merck reported modest growth at 1%, bringing in $65.01 billion as it prepares for the expiration of key patents on its cancer therapy Keytruda in 2028. Pfizer rounded out the top five with $62.58 billion in revenue—a slight decline—while shifting focus toward obesity treatments following challenges related to COVID-19 product sales.
Industry observers note that these results underscore how pharmaceutical companies are navigating patent cliffs, competitive pressures, and evolving healthcare needs through innovation and strategic partnerships.
